Trial reportJapanese journal of cancer research : Gann1999
Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas.
Trial report in Japanese journal of cancer research : Gann, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Wnt signaling in ovarian tumorigenesis.International journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyPooled it
- Review
- TWIST1 induces proteasomal degradation of β-catenin during the differentiation of ovarian cancer stem-like cells.Scientific reports · 2022Article
- The role of glycogen synthase kinase 3 (GSK3) in cancer with emphasis on ovarian cancer development and progression: A comprehensive review.Bosnian journal of basic medical sciences · 2021Review
- Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance.Journal of clinical medicine · 2019Review
- Genetic analysis and phosphoinositide 3-kinase/protein kinase B signaling pathway status in ovarian endometrioid borderline tumor samples.Oncology letters · 2018Article
- Distribution bias analysis of germline and somatic single-nucleotide variations that impact protein functional site and neighboring amino acids.Scientific reports · 2017Article
- Association of a PARK2 Germline Variant and Epithelial Ovarian Cancer in a Southern Brazilian Population.Oncology · 2016Article
- Tissue-Specific Effects of Reduced β-catenin Expression on Adenomatous Polyposis Coli Mutation-Instigated Tumorigenesis in Mouse Colon and Ovarian Epithelium.PLoS genetics · 2015Article
- An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population.Molecular diagnosis & therapy · 2014Article
- Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2014Article
- Wnt/β-catenin pathway is regulated by PITX2 homeodomain protein and thus contributes to the proliferation of human ovarian adenocarcinoma cell, SKOV-3.The Journal of biological chemistry · 2013Article
- MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.Oncogene · 2011Article
- Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.The Biochemical journal · 2011Review
- Integrin regulation of beta-catenin signaling in ovarian carcinoma.The Journal of biological chemistry · 2011Article
- GSK3beta: role in therapeutic landscape and development of modulators.British journal of pharmacology · 2010Review
- Ovarian cancer.Annual review of pathology · 2009Review
- The beta-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression.RNA (New York, N.Y.) · 2008Article
- Comparative proteomic analysis of low stage and high stage endometrioid ovarian adenocarcinomas.Proteomics. Clinical applications · 2008Article
- Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.Journal of clinical pathology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the contribution of the beta-catenin gene to the development of ovarian carcinomas, mutational analysis of exon 3 of the beta-catenin gene was conducted. We analyzed 61 primary ovarian carcinomas, consisting of 49 non-endometrioid-type and 12 endometrioid-type tumors, for genetic alteration of the beta-catenin gene. Five carcinomas showed beta-catenin mutations (S37C, T41I, T41A), including 4 (33%) of 12 endometrioid-type tumors and 1 (14%) of 7 mucinous-type tumors. All of these mutations altered at the serine/threonine residues that are potential sites of GSK3-beta phosphorylation. We detected no carcinomas with interstitial deletion involving exon 3 of beta-catenin. Furthermore, we immunohistochemically studied 27 of the 61 ovarian carcinomas. Both nuclear and cytoplasmic beta-catenin expressions were demonstrated in 4 of the 27 ovarian carcinomas for which tissue samples were available for examination. All 4 cases exhibited mutations in exon 3 of beta-catenin, including a mucinous carcinoma. Our results suggested that beta-catenin gene mutation at potential GSK3-beta phosphorylation sites results in accumulation of beta-catenin protein within the cells and its translocation to nuclei. Accumulated beta-catenin protein may be involved in the development of endometrioid-type ovarian carcinomas, and some mucinous-type ovarian carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.